Research interests
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.[8]
2026
Anjali Rao
Member, AHA Cardio-Oncology Committee
As of 2023 · Current relationship
Member, AHA Cardio-Oncology Committee
As of 2023 · Current relationship
Anjali Rao is an Assistant Professor of Medicine in Cardiology at Northwestern University Feinberg School of Medicine whose clinical interests include cardiac oncology and general cardiology. Her recent scholarly work focuses on cardiovascular complications of cancer therapies, including bispecific T-cell redirecting antibodies, CAR T-cell therapies, and immune checkpoint inhibitors, as well as the role of statins in breast cancer survivors. She earned her MD from UPMC Medical Education in 2015, completed residency there in 2018, and completed fellowship training at the University of Texas Southwestern Medical Center in 2022 and 2023. Rao is certified in internal medicine and cardiovascular disease, speaks Spanish, and is a member of the AHA Cardio-Oncology Committee, the International Cardio-Oncology Society, and ASE. She has been a Fellow of the ACC since 2019.
Reported no external professional relationships for calendar year 2025
Speaks Spanish
Each topic is linked to its supporting source in Sources.
Training includes Fellowship at University of Texas Southwestern Medical Center, Residency at UPMC Medical Education, MD, and Certified in Cardiovascular Disease, plus 1 more record.
Explore education and trainingAs of 2024
As of 2024
As of 2023
As of 2019
As of 2023
As of 2022
As of 2018
Completed 2015
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.[8]
2026
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction[8]
2025
The role of statins in breast cancer survivors.[8]
2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.[8]
2025